NanoViricides Inc., a publicly traded company specializing in the development of broad-spectrum antivirals, has announced the progression of its lead candidate, NV-387, into Phase II clinical trials for the treatment of MPox infection. This decision follows substantial efficacy data in animal studies for multiple indications, including RSV, Influenza, COVID, and Orthopoxviruses. The company has engaged a Clinical Research Organization to conduct the trial, with a site established in the Democratic Republic of Congo. The Clinical Trial Application is nearing completion, and manufacturing of the NV-387 substance is largely finished. The trial aims to expedite the company's pipeline towards revenue generation, with plans to extend NV-387's application to respiratory infections following the MPox trial. Results from this clinical study have yet to be presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.